MSB 1.49% 99.5¢ mesoblast limited

Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-46

  1. 2,363 Posts.
    lightbulb Created with Sketch. 461
    Few highlights from broadcast to date.

    “ unprecedented “ drop in pain for people in desperate need.
    Compared to opiates, significant pain reduction.

    looking for accelerated path with FDA

    Know functional measures needed to move forward.

    P values were significant in reduction change of pain. Self evident. Much stronger . Very positive . Regulators COULD approve straight away.Cannot be ignored by FDA. But might need another study. No alternatives. Could use of opposes hazardous, overdoses doubled. Opioids sparing.

    Business focus
    Will meet with European regulators to consider path forward

    In commercial talks with USA companies.

    Might consider going alone.

    FANTASTIC
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
99.5¢
Change
-0.015(1.49%)
Mkt cap ! $1.136B
Open High Low Value Volume
$1.02 $1.02 99.5¢ $2.005M 1.991M

Buyers (Bids)

No. Vol. Price($)
3 14424 99.5¢
 

Sellers (Offers)

Price($) Vol. No.
$1.00 63643 1
View Market Depth
Last trade - 16.10pm 19/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.